Icon's balance sheet is sound, with its revenue cyclicality and operating leverage each possessing a medium rating. Icon has historically maintained a fairly conservative balance sheet, and it ended ...

Global healthcare standards are driving providers to adopt advanced absorption technologies for superior wound care and medical applicatio ...

Tiziana Life Sciences (TLSA) announced a product development services agreement with Renaissance Lakewood. This collaboration aims to optimize ...

Friday said that it has signed a product development services agreement with Renaissance Lakewood focused on nasal drug delivery. This collaboration aims to optimize the current formulation and ...

Anaheim, Calif. — Medical manufacturers are seeing overall growth in the market as it continues to rebound from high levels of inventory from the COVID-19 pandemic and responds to new drug development ...

As a biologics CDMO focused on developing and manufacturing recombinant protein products using mammalian cell culture ...

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on ...

Consequently, the forecasting effort is typically limited in scope and depth, focusing on broader market potential, rather than detailed product performance. 2. Early development (Phase I and II ...

Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced Karen S. Lynch has been elected to its board of directors, effective February 19, 2025. The appointment ...

Researchers from the National University of Singapore (NUS) have pioneered a new catalytic transformation that converts ...

Early adopters are seeing big gains in drug development ... Research projects that generative AI could boost the pharma and medical-product industries' annual revenues by up to $110 billion ...

Biopharmaceutical CMO Market Rapid outsourcing trends and robust investments in advanced manufacturing drive the biopharmaceutical CMO mark ...